Monarch Medical Technologies Appoints Expert in Pediatric Diabetes to Medical Advisory Board

Monarch Medical Technologies, the leader in precision insulin dosing for optimized inpatient glucose management, has appointed Mark R. Vanderwel, M.D., to its Medical Advisory Board. Joining the board of diabetes experts, Dr. Vanderwel will bring expertise in pediatric endocrinology to support Monarch in the continual advancement of the EndoTool Glucose Management System. EndoTool, a Class II U.S. Food and Drug Administration-cleared, software suite, provides personalized dosing recommendations for inpatient intravenous and subcutaneous insulin therapy and is approved for use with pediatric patients age 2 years and above and weighing 12 kg or more.
 
According to the American Diabetes Association (ADA), three-quarters of all cases of type 1 diabetes are diagnosed in individuals younger than 18 years of age and cases of type 2 diabetes are on the rise in adolescents and young adults. Multiple studies have also confirmed that children and adolescents with diabetes have much higher hospitalization rates and more hospital days than age-matched general population.
 
“The care of children with diabetes and adolescents can differ greatly from the course of care for an adult with diabetes due to their growth and development, physiological and psychological characteristics, and health status,” said Dr. Vanderwel. “These factors, coupled with the stresses of hospitalization, increase the intricacies of caring for this patient population and emphasize the need for an individual approach to care. Working at an organization that has been a longtime EndoTool client, I’ve seen its ability to provide individualized insulin therapy and its positive impact on clinical and financial outcomes firsthand. I’m thrilled to join the advisory board to help guide the company in continued success.”
 
Dr. Vanderwel currently serves as the medical director of the Pediatric Endocrinology Division of Atrium Health in Charlotte, N.C., and has been practicing as a pediatric endocrinologist with the health system since 2005. He earned his bachelor’s degree from Macalester College and his medical degree from the Michigan State University College of Human Medicine. He completed his pediatric residency at Carolinas Medical Center. Following two years of service in the U.S. Air Force as a general pediatrician, he then completed his pediatric endocrinology fellowship at the University of Texas-Southwestern Medical Center of Dallas.
 
Dr. Vanderwel is a frequent speaker on diabetes and the use of insulin and insulin pump therapy, presenting at industry events, grand rounds and local chapter meetings. He also is an active member in industry societies, including the American Diabetes Association, Pediatric Endocrine Society and the American Academy of Pediatrics. Dr. Vanderwel has been named one of Charlotte’s Top Doctors by his peers annually since 2010. He also is a respected teacher, earning three W. Elliott White Teaching Awards presented by the pediatric residents of Atrium Health.
 
“While caring for pediatric and adolescent patients with diabetes present unique aspects of care and management, hospitals now have innovative technology like EndoTool to assist in optimizing glycemic management and reducing length of stay for this patient population,” said Laurel Fuqua, executive vice president and chief clinical officer of Monarch Medical Technologies. “We’re pleased Dr. Vanderwel is joining our medical advisory board to help continue to advance our solutions and support our efforts to assist hospitals in individualized insulin therapy for pediatric and adolescent diabetes. His experience with advanced technologies, diabetes and use of EndoTool will greatly enhance our ability to remain on the cutting edge of precision automated insulin delivery.”
 
Monarch Medical Technologies provides electronic systems for inpatient glycemic management. Monarch’s EndoTool Glucose Management System offers personalized dosing recommendations for intravenous and subcutaneous insulin therapy. EndoTool has enabled more than 250 hospitals to provide unsurpassed patient-specific glycemic control across a broad population of patients, and ultimately deliver better, safer care.